UCB R&D Campus

Abell Nepp are the laboratory planners for a major new headquarters in Surrey for global biopharmaceutical company UCB.

The Design Team led by Heatherwick Studios and executive architect Veretec are now completing RIBA Stage 4 services. Construction is expected to begin in early 2022 with completion at the end of 2024. UCB purchased the Windlesham campus from Abell Nepp’s former client, Eli Lilly and Company who occupied the site for over 50 years.

The existing laboratory buildings will be overhauled to accommodate UCB research and analytical programmes including their extensive use of automation and robotic scientific equipment.

Its relocation to a single integrated site is essential for UCB’s creative scientific activities and will give UCB the space and synergies needed now and in the future. The ambition is to make the Windlesham campus a sustainable one which integrates with and echoes the landscape to create a collaborative and energising environment where innovation can thrive.

October 2021